A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth ...

Some investors could be tempted to sell. I think that's a temptation to avoid. Here's why Eli Lilly is a no-brainer stock to ...

Eli Lilly is studying two weight loss candidates in phase 3 trials, one of which is an oral candidate. Does Viking stand a ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Eli Lilly (NYSE: LLY) saw its stock tumble 8% following a disappointing Q3 earnings report, wiping out nearly $70 billion in ...

I think that's a temptation to avoid. Here's why Eli Lilly is a no-brainer stock to buy on the dip. Concerns about Lilly's Q3 update are overblown It's not surprising that Lilly's shares sank ...

Shares of Eli Lilly (NYSE: LLY) were sinking 6.3% lower ... Should investors consider buying Lilly stock on the dip? I think so. The bull case for Lilly remains intact despite the company's ...